Cancer development is a multistep process involving accumulation of genetic modifications responsible for unregulated cell division, survival and death 1 . Accumulation of genetic mutations results in the expression of tumour antigens that trigger innate and adaptive antitumour immune responses to eliminate cancer cells 2 . The description of tumour-infiltrating lymphocytes (TILs) with effector and memory functions within primary tumours and their metastases and the discovery of the correlation between the density of CD8+ T effector memory cells at the site of the primary tumour and the survival of patients unambiguously demonstrated the importance of the tumour microenvironment (TME) in cancer control 3, 4 . Classically, the generation of an efficient adaptive immune response against cancer occurs in secondary lymphoid organs (SLOs), wherein major histocompatibility complex (MHC) molecule-peptide complexes are presented to CD4 + T and CD8 + T cells by mature dendritic cells (DCs), and requires the migration of DCs from the tumour site to the SLOs 5 . B cells are activated in the SLOs upon antigen binding in primary follicles and receive help from the CD4 + T cells to proliferate and form a secondary follicle that progressively becomes a germinal centre. These steps allow lymphocyte proliferation and differentiation into effector T (T eff ) cells and B memory cells that migrate into the tumour and lead to the destruction of tumour cells 5 . However, studies on the TME revealed further insight into the generation and regulation of the antitumour defences by showing that they occur not only in SLOs but also directly at the tumour site within organized cellular aggregates resembling SLOs 6 called tertiary lymphoid structures (TLSs) 7 . TLSs reflect lymphoid neogenesis occurring in peripheral tissues upon long-lasting exposure to inflammatory signals mediated by chemokines and cytokines. They develop in a variety of pathophysiological situations including autoimmune and infectious diseases, transplanted organs, inflammatory disorders and tumours, driving a range of context-dependent effects. In autoimmune syndromes, TLSs enable the local generation of autoreactive T and B cells and autoantibodies that sustain the pathogenic process [8] [9] [10] [11] . In tissue transplants, TLS presence is associated with chronic rejection through the local production of a memory B cell alloreactive response and the production of antibodies that promote the destruction of the allograft 12, 13 . During infections, studies in mouse models have shown that adaptive immune memory responses favouring antibody-mediated pathogen clearance can be generated in TLSs located within the acutely infected organs 14, 15 , Julien Calderaro 1, 3, 4 and Wolf Herman Fridman 1 Abstract | Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues at sites of chronic inflammation including tumours. Key common characteristics between secondary lymphoid organogenesis and TLS neogenesis have been identified. TLSs exist under different maturation states in tumours, culminating in germinal centre formation. The mechanisms that underlie the role of TLSs in the adaptive antitumour immune response are being deciphered. The description of the correlation between TLS presence and clinical benefit in patients with cancer, suggesting that TLSs could be a prognostic and predictive factor, has drawn strong interest into investigating the role of TLSs in tumours.
A current major challenge is to exploit TLSs to promote lymphocyte infiltration, activation by tumour antigens and differentiation to increase the antitumour immune response. Several approaches are being developed using chemokines, cytokines, antibodies, antigen-presenting cells or synthetic scaffolds to induce TLS formation. Strategies aiming to induce TLS neogenesis in immune-low tumours and in immune-high tumours, in this case, in combination with therapeutic agents dampening the inflammatory environment and/or with immune checkpoint inhibitors, represent promising avenues for cancer treatment.
to a progressive breach of self-tolerance resulting in autoreactive B cell activation, which can be associated with lymphoproliferative disorders such as B cell lymphoma driven by chronic hepatitis C virus infection and Helicobacter pylori-associated gastritis 16, 17 . TLSs are also found in the stroma, invasive margin and/or core of a fraction of different tumour types 7, 18 . They are composed of a T cell-rich zone with mature DCs juxtaposing a B cell follicle with germinal centre characteristics and are surrounded by plasma cells. High endothelial venules (HEVs) similar to those that allow entry of lymphocytes into SLOs can be detected at their vicinity 19 . TLSs represent privileged sites for local presentation of neighbouring tumour antigens to T cells by DCs and activation, proliferation and differentiation of T and B cells, resulting in the generation of effector memory T helper (T H ) cells and effector memory cytotoxic cells, memory B cells and antibody-producing plasma cells [19] [20] [21] [22] [23] . TLS density correlates with that of CD8 + T cells and CD4 + T cells in tumours 22 . Their presence is associated with favourable prognosis in most solid malignancies studied so far, illustrating their capacity to induce a systemic long-lasting antitumour response. In hepatocellular carcinoma (HCC), TLSs located in the adjacent parenchymal tissue correlate with an increased risk of late relapse, and it has been suggested that they could serve as niches that sustain the survival of transformed hepatic cells 4, 24 .
Immune checkpoint blockade to unleash antitumour immune reactions results in unprecedented rates of durable responses in a large set of cancers 25 . However, not all patients respond, and determining accurate biomarkers of response is an urgent medical need. In patients with melanoma and non-small-cell lung cancer (NSCLC) treated with anti-programmed cell death 1 (PD1), an important premise for clinical responses is the presence of pre-existing antitumour T cells and PD1 ligand 1 (PDL1) expression at the tumour site [26] [27] [28] . The CD8 + T cells are held in check by tumour and myeloid cellexpressed PDL1 and can be reinvigorated into effector cells that kill malignant cells in patients under immune checkpoint blockade. Measurement of the number of mutations carried by tumour cells (known as the tumour mutational burden) is another predictive marker associated with response 29 . However, none of these markers are fully predictive of responses to immunotherapies. Being sites for the generation of circulating effector memory cells that control tumour relapse, TLSs provide unique opportunities to guide the next generation of clinical trials in the expanding field of immuno-oncology. Notably, in two studies of NSCLC, post-treatment tumours from patients responding to neoadjuvant anti-PD1 were shown to exhibit enrichment in TLSs 30 , and the presence of tumour-infiltrating PD1 hi CD8 + T cells in TLSs before treatment was predictive of response to anti-PD1 (ref.
31
). Furthermore, clinical responses of patients with cervical intraepithelial neoplasia (CIN) to vaccination against human papilloma virus (HPV), the primary aetiological agent of cervical cancer, are associated with the induction of TLSs in regressing lesions 32 . In addition to being markers of therapeutic immune responses in cancers, TLSs could serve to fuel antitumour immune reactions. Indeed, one could speculate that the induction of TLSs in tumours may facilitate lymphocyte recruitment and tumour control. Thus, TLS induction could be used to open up the field of immuno-oncology treatments to immune-low tumours or immune-high tumours when used in combination with immune checkpoint inhibitors or anti-inflammatory agents. To this end, a series of approaches are being developed using chemokines, cytokines, antibodies, antigen-presenting cells or synthetic agents to promote TLS development in tumours.
In this Review, we provide a comparative analysis of TLS composition, organization and location in human cancers. We focus on the influence of TLSs on the composition of the TME and on antitumour immune responses in primary and metastatic tumours. We leverage this knowledge to discuss how TLSs could be used to predict response to therapies, track with the efficacy of treatments and be targets to manipulate antitumour immune responses. Because spontaneously occurring TLSs have been reported in only a few mouse preclinical models 33, 34 , most of the studies we describe here come from human cohorts, and interpretations of the data derive from correlations.
TLS presence and composition in cancers Analyses in situ. Histopathological records of unspecific lymphocytic infiltration on haematoxylin and eosin (H&E) slides date back to 1967 (ref.
35 ), when an inflammatory reaction was first reported as a prognostic feature of colorectal cancer. However, these reports were not informative of specific subpopulations of immune cells, and it took some time to acknowledge TLSs as key players in the TME. In early descriptions in melanoma 36 and NSCLC 37 , TLSs were found to resemble SLOs, containing a T cell zone with clusters of CD3 + T cells and DC-lysosome-associated membrane glycoprotein (DC-LAMP; also known as LAMP3)
+ mature DCs and a follicular CD20 + B cell zone (Box 1; fig. 1 ). Recent characterization of the B cell follicles in NSCLC and ovarian cancers showed the presence of bona fide germinal centre B cells positive for the proliferation marker Ki67; some of these B cells expressed activation-induced deaminase (AID), the critical enzyme for somatic hypermutation and class switch recombination of immunoglobulin genes, as well as BCL-6, the transcription factor involved in the late stage of B cell maturation 20, 38 . A network of follicular dendritic cells (FDCs) was detected in the germinal centre using CD21 or CD23 labelling. Indeed, the presence of plasma cells (CD38 + CD138 + ) surrounding the follicle and in dense cellular aggregates is highly suggestive of production of antibodies in situ 21 . In breast cancer, CD4 + T follicular helper (T FH ) cells present in close vicinity to germinal centre B cells were found to co-express PD1 and inducible T cell co-stimulator (ICOS), with BCL-6 being the distinguishing transcription factor and interleukin-21 (IL-21) the characteristic cytokine 39 . 
Germinal centre
A specialized compartment within lymphoid structures that promotes B cell proliferation, differentiation, affinity maturation through somatic hypermutation and class switch recombination. They also express a set of mucin-like glycoproteins, ligands of L-selectin (also known as CD62L) expressed by lymphocytes, allowing their homing into tissue 42 . Using L-selectin as a marker to identify TLS T cells, the majority of T cells within TLSs were found to be of an effector memory type in lung tumours, with few central memory T cells and naive T cells; naive T cells, however, were enriched in the TLSs when compared with the rest of the tumour 22 is a robust and specific approach, in our experience, comparison of several signatures generated from mRNA extracted from TLS-positive cancer tissue reveals some heterogeneity of expression. Therefore, there is still a need for the development of robust TLS detection assays using data from mRNA sequencing or transcriptomic analyses of tumour biopsy samples, which would be useful for the follow-up of clinical studies.
Somatic hypermutation
To address the question of TLS heterogeneity among human cancers, we performed a pan-cancer analysis of • Dendritic cells (DCs): DC-lysosome-associated membrane glycoprotein (DC-lAmP; mature DCs), CD83 or CD86 (activated DCs).
• Neutrophils: CD66b or myeloperoxidase.
• macrophages: CD68.
• High endothelial venules (Hevs): peripheral node addressin (PNAd) and meCA79.
Detecting TLSs
• Haematoxylin and eosin (H&e) staining is the simplest technique enabling the detection of TlSs in formalin-fixed paraffin-embedded tumour sections. mature TlSs correspond to lymphoid follicles including a dense cellular aggregate resembling germinal centres found in secondary lymphoid structures (Slos). less differentiated structures such as lymphoid aggregates and lymphoid follicles without germinal centres can also be detected.
• Immunohistochemistry (IHC) on consecutive tumour sections or double or multiplex labelling techniques using the markers listed below followed by evaluation of TlS density, size and cellular content on scanned images using quantitative digital pathology software is commonly used. In some reports, IHC staining was found to be more accurate in the detection of TlSs than H&e staining
94
.
Markers of cell populations used for detection
• DC-lAmP + mature DCs: a marker of TlSs in non-small-cell lung cancer (NSClC) because they are almost exclusively found in these structures in this cancer type. However, DC-lAmP + DCs can be found outside TlSs in other cancers such as clear-cell renal cell cancer or hepatocellular carcinoma.
• CD20 + B cell follicles, adjacent to a CD3 + T cell zone, provide easy and convenient ways to localize TlSs.
Location of TLSs
• TlSs are more abundant in the invasive margin or the stroma than in the core of tumours. Therefore, whole sectioning of a tumour block with the most stromal infiltration is a reliable approach to detect TlSs. Tumour biopsy samples are disadvantageous given the small portion of tissue examined. NATuRe RevIewS | CaNCeR the cellular composition of the TME from The Cancer Genome Atlas (TCGA) data using the deconvolution method MCP-counter 57 . The t-distributed stochastic neighbour embedding (tSNE) map (a means of visualizing high-dimensional data in a low-dimensional space of two or three dimensions) derived from this analysis enables the identification of a series of tumours strongly infiltrated by various TLS-associated populations: B lineage cells, T cells, monocytic cells (particularly myeloid DCs) and endothelial cells ( fig. 2a) . Visualization of the expression of the main chemokine genes associated with TLS neogenesis on this map (CCL19, CCL21, CXCL12 and CXCL13; Box 2), as well as the 12-chemokine gene signature associated with TLS presence (TABLe 1) , reveals similar profiles, with the TLS signature being strongly expressed in tumours with a higher abundance of B lineage cells and T cells, as well as myeloid DCs (fig. 2b ).
Cancer type-specific expression of the 12-chemokine signature ( fig. 2c ) revealed that, in most cancer types, the distribution was extremely heterogeneous, with some tumours expressing the signature at a very high level. For example, lung tumours (lung adenocarcinoma and lung squamous cell carcinoma) revealed a strong expression of the signature, hinting towards a frequent presence of TLSs. However, in some malignancies, the majority of tumours do not exhibit strong expression of the TLS signature. This is notably the case for tumours occurring in immunologically privileged sites, such as the brain (glioblastoma and lower-grade glioma) and the eye (uveal melanoma), although tumours occurring in testis (testicular germ cell tumours) exhibit a remarkably high expression of the TLS signature. In accordance with these findings, healthy brain tissues express low levels of CXCL12, CXCL13 and CCL21, and brain metastases from melanoma and breast cancer contain no or very few TLSs 58, 59 . Other malignancies also presented very low expression of this signature: adrenocortical carcinoma, pheochromocytoma or paraganglioma, and most kidney carcinoma histotypes with the exception of clear-cell renal cell carcinoma. It is noteworthy that adrenocortical carcinomas derive from adrenal glands and secrete corticosteroids that were recently shown to inhibit TLS neogenesis 60 . Lastly, low expression levels of the TLS chemokine signature and a low proportion of TLSs are found in pancreatic cancers, possibly reflecting their fibrotic stroma, which might physically restrict the development of TLSs 61 (TABLe 2) . Altogether, this transcriptomic analysis unveils the heterogeneity of TLS abundance both within and between human cancer types.
TLS functions in cancer
Favourable impact of TLSs on prognosis. Accumulating evidence indicates that TLSs play a major role in controlling tumour invasion and metastasis. A favourable impact of TLS density on overall survival and disease-free survival of patients has been observed irrespective of the detection method on sections of tumour tissue in lung cancer 20, 22, 37, 60 , colorectal cancer 23, 62 , pancreatic cancer 63, 64 , oral squamous cell carcinoma 65 and invasive breast cancer 19, 40, 55, 66, 67 (TABLe 2) . This prognostic impact was independent of pathological tumour-node-metastasis (TNM) staging for lung 22 Adrenal glands endocrine glands producing hormones that participate in the regulation of the immune system, metabolism and stress. These glands secrete notably cortisol, aldosterone and androgenic steroids.
www.nature.com/nrc CD8 + T cells with effector memory phenotype and by overexpression of a set of genes characteristic of T cell activation, T H 1 cell skewing, T cell chemotaxis and T cell cytotoxicity when compared with TLS low tumours 19 69 and invasive breast ductal carcinoma 70, 71 . Chemoattractant CXCL13-producing PD1
+ T FH cells known to help facilitate B cell responses were detected close to TLS B cells in breast cancer and in soft tissue sarcoma 39, 72 . Plasma cells, notably present at the periphery of TLSs 20, 39 and in dense aggregates in the tumour stroma 21 , produce antitumour antibodies of the IgG isotype in vitro; IgA secretion
Box 2 | Genesis of tertiary lymphoid structures
The genesis of tertiary lymphoid structures (TlSs), which has mainly been elucidated using preclinical mouse models, has similarities with that of secondary lymphoid organ (Slo) formation 6, 133 . local production of the chemokine CXC-chemokine ligand 13 (CXCl13) and the cytokine interleukin-7 (Il-7) by lymphocytes or stromal cells recruits lymphoid tissue inducer (lTi) cells to the site of inflammation 134 . T helper 17 (T H 17) cells 135, 136 , B cells 137 or m1-polarized macrophages 138 have been shown to be able to substitute for lTi cells in the initiation of TlS genesis in various pathological contexts. These lTi cells interact with local stromal cells, comparable to lymphoid tissue organizer cells in Slos, particularly through lymphotoxin-α 1 β 2 (lTα 1 β 2 ) binding to the lTβ receptor (lTβR) 139 . This signalling pathway leads to secretion of vascular endothelial growth factor C (veGFC) by stromal cells 140 , therefore promoting high endothelial venule (Hev) development, as well as the secretion of adhesion molecules, such as vascular cell adhesion molecule 1 (vCAm1), intercellular adhesion molecule 1 (ICAm1) or mucosal addressin cell adhesion molecule 1 (mADCAm1). The combined action of lTβ-lTβR signalling and Il-17 secretion by lTi cells leads to the production of various chemokines, notably CXCl12, CXCl13, CC-chemokine ligand 19 (CCl19) and CCl21. Together, these chemokines induce expression of lTα 1 β 2 on lymphocytes 141 , recruit lymphocytes from nearby Hevs 142 and govern their organization into T cell and B cell zones. A proportion of the CD4 + T H cells become polarized into T follicular helper (T FH ) cells. Type I interferon and Il-1 also induce CXCl13 production 100, 143 . Il-17R, IL-17 receptor. has also been described in NSCLC, ovarian cancer and gastric-oesophageal adenocarcinoma 20, 38, 48, 69 .
Altogether, these studies demonstrate that TLSs enable the generation of effector and memory B cell responses against tumour antigens, leading to antibody production.
In .
Cross presentation by B cells to CD8
+ T cells has been described, including for the cancer testis antigen NY-ESO-1 (ref. 74 ), and engagement of the receptors B7 (also known as CD80) and CD40 on B cells replaces the need for CD4 + T cells to transmit help to CD8 + cytotoxic T cells in viral and antitumour responses [75] [76] [77] . 81 . Because the aetiologies of these cancers are most likely independent of this set of viruses, these bystander TILs may have been generated earlier in response to viral infections.
TLSs and chronic inflammation: dual role of TLSs in hepatocellular carcinoma. Chronic inflammation driven by chemicals such as asbestos and cigarette smoke or by infectious agents such as bacteria or viruses supports tumour progression, invasion and metastasis 82 . TLS development occurs at sites of chronic inflammation and is amplified by pro-inflammatory cytokines. HCC represents an exemplar of inflammation-driven cancer characterized by cirrhotic nodules with abundant TLSs in the non-tumoural tissue 83 . In one study, expression of a 12-gene signature of TLS and detection of TLSs in the liver tissue adjacent to the tumour were found to be linked to an increased risk of late recurrence in 82 patients with HCC treated by surgical resection 24 . Late recurrence of HCC, occurring 2 years after surgery, is considered to represent de novo carcinogenesis from the inflamed liver, while early recurrence, within 2 years of surgery, results from the dissemination of residual primary tumour cells. Using a mouse model of persistent nuclear factor-κB (NF-κB) activation in hepatocytes leading to hepatitis and the development of TLSs before the formation of HCC nodules, Finkin et al. 24 showed that TLSs can serve as niches for malignant hepatocyte progenitors. These HCC progenitor cells were also detected in human HCC specimens 24, 84 . This finding demonstrated a role for TLSs in the pre-malignant phase of tumour growth, contrasting with their favourable impact on the clinical outcome of patients in a series of other cancer types 4, 85 (TABLe 2 ). An inflammatory context that may sustain TLS formation in the peri-tumoural stroma of HCC tumours has also been detected [86] [87] [88] . However, the presence of bona fide TLSs in the tumour zone of HCC, but in lower densities than those occurring in the adjacent parenchyma, was recently described by us in 2 different cohorts (490 patients in total) 89 . In contrast to the results obtained in the non-tumour liver tissue, TLSs in the tumour core were predictive of a decreased risk of early relapse by univariate and multivariate analyses 89 . The risk of recurrence was also negatively correlated with the degree of TLS maturation, with fully formed primary or secondary follicles providing a better protection than mere lymphocytic aggregates, findings that were further validated by gene expression profiling using a public data set (221 patients). By contrast, we found that TLSs in liver tissue adjacent to the tumour had no prognostic value for early and late recurrence (217 patients analysed) 89 . Altogether, these data highlight the impact of TLS location on prognosis, with TLSs located in the non-tumour liver contributing to a pro-tumoural, inflammatory state, whereas intratumoural TLSs truly reflect ongoing, effective antitumour immunity ( fig. 3 ).
TLSs during tumour progression. The link between
TLSs and histopathological parameters has been investigated and reveals discordant observations. In primary tumours from 225 patients with melanoma, the presence of HEVs correlates with good clinical characteristics, including a thin Breslow thickness, a low Clark level of invasion and tumour regression 90 . In a study of 80 patients with oral squamous cell carcinoma, TLSs were more abundant in T1 and T2 stages than in T3 and T4 stages 65 . By contrast, TLS presence correlates with higher tumour grade, stage and TIL densities and does not significantly impact on survival in other cancers (TABLe 2) . For example, the abundance of TLSs increases in advanced stages (II-IV) compared with stage I gastric cancer (171 patients analysed) 33 . A pilot study (28 patients) indicated that TLSs were more common in high-grade muscle-invasive bladder cancer than in the non-muscle-invasive cancers 91 . In breast cancer, high-grade tumours were found to be twice more prone to exhibit TLSs than low-grade tumours, and the most aggressive tumour grade, grade 3, is an independent predictor for TLS formation in patients with human epidermal growth factor receptor 2 (HER2; also known as ERBB2) − tumours 66, 92, 93 . Nevertheless, the link between the presence of TLS and tumour grade and the decrease in prognostic value of TLSs during tumour progression do not occur in all cancers, with TLSs being found to retain their prognostic value with high prognostic impact in advanced NSCLC 22 , pancreatic cancer 63 and colorectal cancer 62 in large cohorts (TABLe 2) .
Several mechanisms can operate to blunt the beneficial impact of TLSs in high-grade or high-stage tumours. In a cohort of 248 patients with invasive breast cancer, 37.5% presented with TLSs, inside which tumour cells were detected in 42% of patients 92 . The presence of tumour cell-infiltrated TLSs was associated with Fig. 2 | Pan-cancer gene expression analysis of tertiary lymphoid structure markers in 9,880 tumours. This primary analysis was conducted by the authors for the present Review. a | t-distributed stochastic neighbour embedding (tSNE) map of 9,880 tumours from The Cancer Genome Atlas (TCGA) based on the MCP-counter software scores estimating the composition of the tumour microenvironment (TME). The left graph shows the cancer type of each of the samples. The six graphs on the right display the expression level of six MCP-counter cell signatures related to tertiary lymphoid structures (TLSs). To build this map, RNA-sequencing data from TCGA samples of indicated pathologies were obtained from the National Cancer Institute (NCI) Genomic Data Commons (GDC) and normalized as transcripts per million (TPM). MCP-counter 57 software was applied to all samples, and the tSNE map was constructed on the estimates with the R package tSNE. This part of the figure illustrates the strong heterogeneity of cancer types in terms of TME composition. b | Expression levels of CC-chemokine ligand 19 (CCL19), CCL21, CXC-chemokine ligand 12 (CXCL12), CXCL13 and the 12-chemokine signature on the tSNE map presented in part a. Several cancer types with a strong expression of signatures related to TLS populations can be observed. c | A violin plot showing the expression of the 12-chemokine TLS signature in the various cancer types as probability densities. The expression is displayed as the mean of the log 2 (TPM + 1) of the 12 genes of the signature. ACC, adrenocortical carcinoma; BLCA , bladder carcinoma; BRCA , breast carcinoma; CESC, cervical squamous carcinoma; CHOL , cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA , oesophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear-cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, lower-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumour ; THCA , thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
Breslow thickness
A measure in millimetres of the distance between the upper layer of epidermis and the deepest point of a tumour. This staging system is used as a prognostic factor for melanoma.
Clark level of invasion
A staging method used conjointly with the Breslow thickness to describe the depth of melanoma tumour invasion into the skin. . Other non-mutually exclusive possibilities include the fact that TLS presence cannot subvert the immunosuppressive influence of the TME in highly inflamed tumours and that TLS composition varies during tumour progression. So far, few studies have investigated the correlation between TLS abundance and T cell exhaustion in the TME as well as the presence of immunosuppressive cells within TLSs. However, an increased expression of exhaustion molecules occurring in tumours with abundant TLSs has been described in triple-negative breast cancer and HER2 + subtypes of breast cancer, which are more frequently extensively immune infiltrated and exhibit higher tumour cell proliferation and hormone receptor negativity 94 . Furthermore, the expression of PDL1 mostly found on immune cells correlates with the presence of TLSs and the extent of TIL infiltration in these aggressive tumours 94, 95 . Indeed, T reg cell and/or myeloid-derived suppressor cell (MDSC) presence within TLS could exert a negative influence on the capacity of TLSs to generate effector and memory lymphocytes. TLS T reg cells were detected in breast, prostate, lung and colorectal cancers 46, 49, 96 . High numbers of forkhead box P3 (FOXP3) + T reg cells within lymphoid aggregates surrounding primary tumours was indicative of an increased risk of disease relapse and death in 191 patients with breast cancer 46 , and a decreased number of TLS T reg cells correlated with regression in a pilot study of 17 patients with evanescent prostate cancer 49 . In mice, the recruitment of FOXP3 + T reg cells and MDSCs to lymphoid aggregates in B16 melanomas engineered to express CCL21 was found to correlate with the promotion of tumour growth 97 , whereas depletion of TLS T reg cells enhanced the co-stimulatory capacity of DCs, T cell proliferation and protective antitumour immune responses, leading to tumour regression in a spontaneous lung adenocarcinoma mouse model 34 . In addition, depletion of T reg cells was also associated with HEV development, higher TIL densities and reduced tumour growth rates in methylcholanthrene-induced fibrosarcomas in mice 98, 99 . As alluded to above, an enrichment of TLSs has been described in patients with gastric cancer with more advanced stages (II-IV) using TCGA data sets and a three-chemokine gene signature (CXCL13, CCL19 and  CCL21) 33 . Yet, correlation of the expression of this TLS signature with patient survival lacked statistical significance. In a mouse model of gastric tumours driven by a mutated form of gp130 (also known as IL-6Rβ) that induces hyperactivation of the transcription factor signal transducer and activator of transcription 3 (STAT3) in response to the IL-6 family of cytokines, it was found that the appearance of adenomas peaks with the induction of expression of the TLS gene signature and correlates with the development of TLSs in the submucosal tissue, showing the key role of inflammation in TLS formation in this model 33 . TLSs were detected in the gastric submucosa in patients with adenocarcinomas but not in patients with precursor lesions associated with gastritis 33 . The transcription factor STAT3 favours induction, maintenance and effector function of T H 17 cells. Studies in mouse models suggest that the role of this cell subset and of IL-17 in infection-driven and autoimmunity-driven TLS neogenesis depends on the source of antigen or the inflammatory stimulus 100 . In gastric cancer, submucosal TLS development was found to be independent of IL-17 (ref.
101 ). Therefore, other cytokines linked to T H 17 cell polarization, such as IL-1, IL-22 and IL-23, may be involved in TLS formation 100, 102 . Clear-cell renal cell carcinoma belongs to the few tumour types in which high densities of CD8 + T cells correlate with poor clinical outcome 4, 103 . In contrast to NSCLC, most of the DC-LAMP + DCs (80%) were found outside the TLSs (non-TLS DCs), did not express CD83, a marker of mature DCs, and had a low expression of MHC class II antigens, suggesting a lack of DC maturation in these tumours. Tumours with high densities of non-TLS DCs were characterized by advanced Union for International Cancer Control (UICC) TNM stages and fuhrman grades, high densities of macrophages and PD1 + CD8 + T cells, and higher PDL1 and PDL2 expression levels on tumour cells associated with poor patient clinical outcome [103] [104] [105] . Yet, increased densities of TLS DCs identified a small group of patients with high CD8 + T cell densities and low risk of recurrence and death 103 . Although this finding needs to be confirmed in a larger set of patients, a negative correlation between the density of TLS DCs and infiltrating PD1 + T cells was found, suggesting an opposite link between TLS abundance and T cell exhaustion in clear-cell renal cell carcinoma 103 .
TLSs in metastases.
To date, data addressing the question of the role of TLSs in metastatic sites are scarce and discrete. However, the published analyses when gathered together present convergent information with emerging characteristics. First, TLSs are found in a proportion of metastatic sites of several cancer types, strengthening the concept that antitumour immunity is acting in advanced cancers at the metastatic level. The density of TLSs in metastases seems to depend on both the primary tumour type and the organ in which the metastatic site is located. Thus, TLS densities in lung metastases from different tumour types are highly variable and seem to mirror those of the primary sites, being at high densities in metastases from colon and prostate cancers, intermediate densities in metastases from thyroid, renal, liver and breast cancers and very low densities in metastases from leiomyosarcoma and osteosarcoma 10, 106 . In addition, the organ in which a metastasis seeds and grows also influences the density and maturation of TLSs. In melanoma, it has been reported that only skin metastases exhibit fully developed TLSs with proliferating B cells and AID expression; by contrast, FDCs were detected in some lung, muscle and gut metastases but not in brain metastases 58 . In breast cancer, analysing a large cohort of 355 metastases from 4 metastatic sites (lung, liver, brain and ovary), Lee et al. 59 reported that TLSs can be found in lung and liver metastases but not in brain and ovarian metastases.
When present at metastatic sites, TLSs have the same characteristics as in primary sites. Their density correlates with high T cell infiltration in the tumour, often with a T H 1 cell and cytotoxic T cell skewing 10, 48, 59, 82, 96, 106, 107 . The role of B cells is beginning to be addressed. In microdissected follicles from melanoma skin metastases, B lymphocytes showed a clonal amplification, rearranged immunoglobulin genes, somatic hypermutation and isotype switching, supporting the concept of a local antigen-driven B cell response 48 . Surprisingly, isotype switching occurred not only to IgG subclasses but often to IgA, despite the nonmucosal site of the metastasis. This frequent IgA production, also found in TLS-rich primary NSCLC tumours, may be due to high levels of transforming growth factor-β (TGFβ) produced in cancers 20 , which acts as the switch factor for IgA 108 . In omental metastases from high-grade serous ovarian cancer, memory B lymphocytes essentially located within TLSs had a higher clonality and somatic hypermutation rate than non-tumour B cells, and they produced chemokines attracting DCs, T cells and natural killer cells; the density of B cells also correlated with that of mature DC-LAMP + DCs in the stroma of these tumours and with an immune cytolytic signature 48 . Furthermore, plasma cells were present, and IgG, IgM and IgA deposits were found on tumour cells. These antibodies, likely produced by germinal centre-generated plasma cells in TLSs, reacted with tumour-associated antigens 48 , as reported in primary NSCLC 20 . Finally, as for their prognostic impact, TLSs in metastatic sites parallel that of primary tumours. Their density correlates with prolonged survival in patients with lung 106 and liver 96 metastases from colorectal cancer, lung metastases from breast cancer 59 and omental meta stases from high-grade serous ovarian cancer 48 , and DC-LAMP + DC density correlated with a shorter survival in lung metastases from clear-cell renal cell carcinoma 106 (TABLe 2) . Altogether, data emerging from studies specifically looking at metastatic sites have illustrated the diversity of situations but support the general findings established with TLSs in primary tumours, showing that the tumour type, the organ, the degree of TLS maturation, their location with the TME and the inflammatory context of the cancerous site are essential parameters for their clinical impact.
TLSs in cancer therapy
A large array of data supports the idea that cancer therapies that stimulate antitumour immune responses are most effective at producing long-term responses 4, 109 . Although self-evident for immunotherapies 27, 110 , this concept has gained strength when also considering conventional chemotherapies 111 , radiation therapy 112, 113 and targeted therapies 114 . With TLSs being a paramount characteristic of the immune contexture of tumours 109 , as they represent major sites where antitumour immune responses are generated 7, 18 , it has become necessary to assess their impact on response to treatment and their modulation by therapies. It is likely that the analysis of TLS densities, their location at the vicinity of or at a distance from tumour beds, their composition and degree of maturation, their impact on T and B cell receptor clonality within tumours and the antibodies produced by plasma cells educated in TLSs will become essential to predict therapeutic responses and to evaluate the efficacy of treatments. However, to date, there are only limited reports on these aspects. In another cohort of 1,058 patients with breast cancer, the analysis of pretreatment core biopsy samples showed that high densities of both T and B lymphocytes, with the latter likely being located within TLSs, correlated with pCR induced by neoadjuvant therapy 115 . Similar findings were reported in a cohort of 108 patients with triple-negative breast cancer treated with neoadjuvant chemotherapy in which TLS density, CD8
+ and CD20 + cell densities and CXCL13 gene expression correlated with pCR 116 . In a cohort of 117 patients with hormone receptor-negative, HER2
+ breast cancer treated with adjuvant trastuzumab (anti-HER2 therapy), TIL density was associated with TLS-rich tumours and correlated with longer disease-free survival 66 .
The clinical impact of TLSs on responses to therapies has very recently been extended to other cancers and to immunotherapies (W.H.F., unpublished observations). It is interesting to note that a high proportion of desmoplastic melanomas exhibit TLSs 117 and that this tumour type also has a high response rate to PD1 blockade 118 . Therapeutic modulation of TLSs and its impact on clinical outcome. The effect of cancer therapies on TLSs and the resulting potential impact on patient clinical outcome have begun to be explored. In the Kras LSL−G12D/+ Trp53 −/− (KP) genetically engineered mouse model of lung cancer, hypo-fractionated radiotherapy induces an early reduction in TLS densities followed by their restoration within 2 weeks 119 . Two independent studies of human NSCLC reported that TLSs present in lesions regressing after neoadjuvant anti-PD1 therapy 30 or chemotherapy 120 were associated with longer disease-free survival and overall survival 120 . By contrast, caution should be taken with using associated therapies, such as corticosteroids, often used to manage the side effects of chemotherapy, www.nature.com/nrc as they have been reported to decrease TLS density in lung squamous cell carcinoma and to impair the positive clinical impact 60 . The combination of antiangiogenic and anti-PDL1 therapies increased HEV formation and subsequent TLS formation in experimental models of breast cancer and neuroendocrine pancreatic tumours 121 . These data support the requirement for intratumoural TLSs to support the efficacy of reinvigorated antitumour responses by immune checkpoint antibodies.
The fact that TLSs may be a major component in the induction of antitumour immunity is illustrated by vaccine trials. Therapeutic vaccination of patients with high-grade CIN2-CIN3 against the E6 and E7 proteins of HPV16 and HPV18 induced TLS formation in the stroma subjacent to residual intraepithelial lesions, in which proliferating lymphocytes were found. Furthermore, clonally expanded T cells, educated in the tumourpossibly in TLSs -were identified within lesions but not in the blood. Such clonal expansions were not found in lesions of non-vaccinated patients 32 . In PDAC, which is considered to be a poorly immunogenic tumour, therapeutic vaccination with an irradiated, allogeneic granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting pancreatic tumour vaccine (GVAX) induced TLSs in 33 of 39 patients 2 weeks after treatment. Subsequent gene expression analysis of the microdissected TLSs identified pathways regulating immune cell activation and trafficking, a suppressed T reg cell induction pathway and an enhanced T H 17 cellstimulating pathway correlating with improved survival, anti-mesothelin T cell responses and an increased intratumoural T eff cell to T reg cell ratio 122 . These data demonstrate the potential role of TLSs in converting non-immunogenic tumours into immunogenic neoplasms (fig. 4) .
TLS induction to increase the antitumour immune response. Given the data outlined in the previous subsection, it is tempting to consider the development of strategies aimed at inducing TLS neogenesis in tumours to enable the education of intratumoural T and B cells into effector and memory cells capable of recognizing the tumour. A series of recent reports using mouse models have investigated this possibility. Because TLSs develop in inflammatory sites, TNF family members are currently being used for this purpose. The lymphotoxin (LT), a member of the TNF family, system is a key regulator of lymphoid architecture (Box 2), and the LT-LIGHT (also known as TNFSF14) signalling axis delivers critical signals for the differentiation of reticular networks into fibroblastic reticular cells (FRCs) and FDCs. In the RIP1-Tag5 mouse model of pancreatic cancer, in which tumour immunity is limited by the inability of T cells to infiltrate tumours in sufficient numbers to affect tumour growth, targeting LIGHT to tumour vessels by using a vascular targeting peptide (VTP) normalizes the vasculature, enables the influx of endogenous T cells and induces the de novo formation of intratumoural TLSs and protective immunity 123 . In addition, LIGHT-VTP enhances efficacy of anti-PD1 and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) immune checkpoint blockade by inducing a large number of intratumoural effector and memory T cells with resultant survival benefit, while the addition of a tumour vaccine achieved maximal therapeutic efficacy in this model 123 . Delivery of DCs engineered to express the T cellspecific T box transcription factor T-bet into sarcoma tumour lesions (MCA205 xenografts) of mice promotes lymphocyte infiltration, T H 1 cell skewing and the development of TLSs and slows tumour growth 124, 125 . This process is IL-36γ-dependent, as this therapeutic strategy fails when given to wild-type mice that are coadministered an IL-36 receptor antagonist or when given to IL-36-deficient mice 125 . Interestingly, IL-36γ expressed in endothelial cells also correlates with the maintenance of follicular B cells in human colorectal cancers 126 . Thus, T-bet-based and IL-36γ-based therapeutics may represent attractive tools to favour TLS formation. In addition, intratumoural delivery of CCL21 gene-modified DCs was shown to reduce tumour burden in a transgenic mouse model of spontaneous bronchoalveolar cell carcinoma 127 and elicit systemic tumour-specific immune responses and intratumoural CD8 + T cell infiltration in patients with lung cancer 128 . The HEVs surrounding the TLSs allow lymphocyte entry into tumours. Therefore, therapeutic strategies aimed at enhancing this feature would be advantageous to improve antitumour immune responses. In mouse models, depletion of T reg cells induces HEV formation 98 and T cell infiltration and activation, leading to tumour destruction 34, 98 , and it has been suggested that T reg cells have an important role in negatively regulating antitumour immune responses within TLSs 34, 98 . In preclinical mouse models of breast and pancreatic cancers and of glioblastoma, the addition of anti-vascular endothelial growth factor receptor 2 (VEGFR2), anti-PDL1 and agonistic anti-LTβ receptor (LTβR) therapies was found to induce HEVs and enhanced cytolytic activity, resulting in tumour destruction and effectively transforming immune cold glioblastomas into immune-rich tumours 121 .
Other strategies have utilized stromal cells derived from lymph nodes to induce TLSs, exploiting their architectural support, lymphogenesis and lymphocyte recruitment properties (Box 2). The subcutaneous injection of a stromal cell line derived from lymph nodes induces TLSs that attract infiltration of host immune cell subsets and can improve the antitumour immune response against MC38 colon cancer xenografts in mice 129 . Several teams are also working on the development of synthetic scaffolds for cancer immunotherapy, aiming to induce immune responses locally, inside the tumour. In this regard, the 12-chemokine gene signature provides a good starting point for the potential construction of designer TLSs 130 . Various modified lymph node-derived cell lines are being combined with tumour antigen-pulsed DCs and then incorporated into biocompatible scaffold materials. When administered to tumour-bearing mice as injectable or implantable matrices, they can promote systemic antitumour immunity 131, 132 . This nascent technology may be used in the future to induce TLSs in immune-low tumours and in immune-high tumours in combination with therapeutic agents dampening the inflammatory environment and/or with immune checkpoint inhibitors (fig. 4 ).
Conclusion and perspectives
It has become evident that TLSs are a major player in antitumour immune responses. Located in the vicinity of tumour nests, and sustained by tumour-associated inflammation, TLSs represent privileged sites for presentation of neighbouring tumour antigens by DCs and education of subsequent T and B cell responses, resulting in the generation of T effector memory cells, memory B cells and antibodies. The full repertoire of antitumour immune responses orchestrated by TLSs and SLOs remains to be deciphered, as does their interrelationship and respective dynamics during tumour progression. Usually correlating with favourable clinical outcome, TLS presence or their induction following cancer therapies predicts therapeutic responses; TLSs are also of paramount importance as a prognostic factor. Lastly, the ability to induce TLS formation through various pharmacological approaches represents a means of increasing the sensitivity of immune cold tumours to immunotherapies when used in conjunction with immune checkpoint blockade, vaccines, viruses, local intratumoural agents or intervention therapies. Conversely, in immune hot tumours with a disturbed TME with strong chronic inflammation, angiogenesis and a fibrotic stroma, the use of antiangiogenic and anti-immunosuppressive agents may help normalize the immune contexture, favouring TLS formation and therapeutic response to immune checkpoint blockade. 
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